Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs Placebo to Prevent Cerebral Ischemia in Low Grade aSAH
NCT07821008Phase 3Not yet recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in aneurysmal subarachnoid hemorrhage (SAH) comparing Ticagrelor with Placebo (2 arms). Primary endpoints: Peri-procedural thromboembolic events at 24 hours and Neurological deterioration due to DCI at 14 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ticagrelor
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT07821008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07821008.